Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey

Cottin, Vincent

doi:10.1183/09059180.00001914

Cited by 29 publications

(27 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar needs have been identified in other studies in IPF. For example, the difficulties faced by HCPs in reliably diagnosing IPF [13,[18][19][20], the need for improved multidisciplinary care [21][22][23], the need for improved access to treatment [24], the need for improved awareness of clinical guidelines [18,25] and the need for improved palliative care [26]. This initiative also emphasised the need for improved disease awareness and information, consistent with two recent PG-informed reports from the British Lung Foundation [14,27,28].…”

Section: Discussionmentioning

confidence: 65%

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers

et al. 2015

View full text Add to dashboard Cite

Patient advocacy groups play an important role in supporting patients with chronic diseases and promoting better care. The aim of this patient-physician initiative was to gather perceptions from European idiopathic pulmonary fibrosis (IPF) patient advocacy groups regarding inequalities and unmet needs in IPF care, in order to develop a Patient Charter to advocate for better care.In total, 11 European patient advocacy groups were interviewed regarding the care of patients with IPF in their countries. Interview feedback was presented to a Working Group including patient advocacy group representatives and IPF specialists; key areas of agreement were developed into the European IPF Patient Charter.The interviews identified five key themes that fed into the final Charter: the need for improved diagnosis, treatment access, holistic care, disease awareness and palliative care. The final Charter was endorsed by patient advocacy groups and presented to 26 Members of the European Parliament in September 2014. It has received >8900 signatures to date.This patient-physician initiative highlights the inequalities and unmet needs in IPF care across Europe, and demonstrates how this insight can inform the development of a Patient Charter, designed as a call to action for healthcare policymakers to drive improvement in European IPF care. @ERSpublications European IPF Patient Charter details unmet needs in IPF and presents a call to action for healthcare policymakers

show abstract

Section: Discussionmentioning

confidence: 65%

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This percentage was even higher in the first AIR survey, reaching 49 % in total [3]. Increased availability of antifibrotic drugs in France and other Western European countries has reduced the use of other therapies in follow-up to 7% [4].…”

Section: Discussionmentioning

confidence: 95%

“…The idea of performing this survey was prompted by the 2013 Advancing IPF Research (AIR) survey arranged by Vincent Cottin, whose results were published in 2014 [3]. The aim of this survey was to assess current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) by experienced physicians.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Idiopathic Pulmonary Fibrosis (IPF)―Common Practice in Poland before the “Antifibrotic Drugs Era”

Piotrowski

Martusewicz-Boros²,

Białas

et al. 2017

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and debilitating lung disease with a median survival time of 3-5 years. For now, pirfenidone (PIR) and nintedanib (NTB) are the only drugs that can slow down the disease's progression. In Poland, these drugs, although registered for legal use, had not been reimbursed for IPF patients until the end of the year 2016. Aim of the study was to assess what was common practice in terms of diagnosis and treatment in the period before antifibrotic drugs became available for IPF patients in Poland. Material and methods:We performed a survey among participants of two nationwide pulmonological congresses held in 2016. Results: One hundred and fifty physicians took part in the study. Only 55% of respondents would reach their final diagnosis in collaboration with a radiologist. Just 40% of those sending patients for surgical lung biopsy (SLB) would discuss the case directly with a pathologist. 22% would never refer the patient suspected of having IPF for SLB. 85% believed that bronchoalveolar lavage (BAL) may be useful for diagnosis. 41% of respiratory professionals would not use any drug for the treatment of IPF patients. 23% of physicians would prescribe corticosteroids in high doses (CS), either in monotherapy or in combination with other drugs. Only 43% of respondents would use antacid drugs in case of symptomatic gastro-oesophageal reflux disease (GERD), and only 11% would prescribe these drugs regardless of GERD diagnosis. Conclusions: The majority of Polish pulmonologists were not supported by radiologists and pathologists in the diagnostic process. Treatment standards were unsatisfactory, mostly due to a lacking of reimbursement regulations. Further education is necessary to improve management of IPF patients in Poland.

show abstract

“…This contrasts to a French survey reporting that 56% always involved a MDD, 37% sometimes involved MDD, and only 7% never involved MDD in the diagnosis of IPF. 22 In another recent survey from France, Cottin et al reported that MDD was never used by 4%, often used by 20%, and always used by 60% of survey respondents. 23 Therefore, our results suggest that, although MDD access and utilization may be quite high in Canada (80% of respondents), there remain a substantial number of practitioners without access to MDD in comparison to other developed countries.…”

Section: Discussionmentioning

confidence: 99%

Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada

Weatherald

McFadden

Fell

2017

Canadian Journal of Respiratory, Critical Care, and Sleep Medic

View full text Add to dashboard Cite

Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey

Cited by 29 publications

References 12 publications

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers

Idiopathic Pulmonary Fibrosis (IPF)―Common Practice in Poland before the “Antifibrotic Drugs Era”

Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada

Contact Info

Product

Resources

About